How to Capture Market Share Through Data-Driven Drug Discovery

How to Capture Market Share Through Data-Driven Drug Discovery

For years pharmaceutical companies have taken existing drugs and repurposed or repositioned them to create new drugs. These new drugs are often geared towards neglected therapeutic areas. Drug repurposing has always been a solid “go to” strategy and a proven method for mitigating the financial risk of drug discovery and a means of addressing softening market share.…

Read More
M&A in Pharmaceuticals and Medical Devices: How to Stop Value Leakage

M&A in Pharmaceuticals and Medical Devices: How to Stop Value Leakage

Most pharmaceutical executives would argue that M&A is critical to drive shareholder value. Transactions can help realize new discovery capabilities, procure new compounds to strengthen stagnant drug development pipelines, or save money, all of which can create a competitive advantage in the market.  The numbers speak for themselves. In 2015, healthcare M&A increased 66%, reaching a...

Read More
In the “Buy vs. Build” world of Pharma, Does Lab Productivity Still Matter?

In the “Buy vs. Build” world of Pharma, Does Lab Productivity Still Matter?

The cost of developing new drugs averages about $500,000 a day over 12 to 14 years (~$2.5B average cost per new drug). This high development spend has not translated into a meaningful number of additional new medical entities approved by the FDA (about ~35 per year). High development costs and thin pipelines have led many companies to shift towards a strategy of acquiring new drugs by...

Read More
Phone: 312-602-4000
Email: marketing@westmonroepartners.com
222 W. Adams
Chicago, IL 60606
Show Buttons
Share On Facebook
Share On Twitter
Share on LinkedIn
Hide Buttons